Chronic inflammatory demyelinating polyneuropathy (CIDP) is the most common chronic immune-mediated neuropathy. It affects ...

CIDP treatment focuses on reducing and slowing the immune processes damaging your peripheral nervous system. It includes corticosteroids, intravenous immunoglobulin, and plasma exchange, but new ...

Vyvgart Hytrulo is FDA-approved for the treatment of chronic inflammatory demyelinating polyneuropathy (CIDP). It is given once a week as a shot under the skin. Vyvgart Hytrulo may also be ...

California Plasma Coalition (CalPlasma) is working to address barriers to source plasma donations and help save more lives.

Argenx is urging patients to “Live Vyvidly.” The biotech put the message out in a direct-to-consumer TV ad that paints ...

Netherlands biotech Argenx has a second FDA approval for its FcRn inhibitor Vyvgart Hytrulo, adding a new indication in chronic inflammatory demyelinating polyneuropathy (CIDP) for a drug that it ...

Heading into 2025, the chief item on argenx’s agenda is the FDA’s April 10 target action date to decide on the approval of a ...

A LOCAL personal trainer wants to spread awareness of a rare disease he was diagnosed with that can severely affect motor ...

Blue Trust Inc. trimmed its holdings in argenx SE (NASDAQ:ARGX – Free Report) by 55.4% in the 4th quarter, HoldingsChannel ...

Chronic inflammatory demyelinating polyneuropathy is an immune-mediated neuropathy that affects the peripheral motor and sensory nerves. The symptoms are of a slowly progressive numbness and tingling ...

Its presenting symptoms may be similar to other conditions affecting the nervous system, which include motor neuron disease, diabetic polyneuropathy, and Guillain-Barre syndrome (GBS). Generally ...

Chronic inflammatory demyelinating polyneuropathy (CIDP) diagnoses are frequently missed or delayed and standard treatments - ...